Literature DB >> 7521344

Regulation of insulin-like growth factor (IGF) binding protein-5 in the T47D human breast carcinoma cell line by IGF-I and retinoic acid.

J Shemer1, A Yaron, H Werner, Z M Shao, M S Sheikh, J A Fontana, D LeRoith, C T Roberts.   

Abstract

The T47D human breast carcinoma cell line has been shown to synthesize insulin-like growth factor-I (IGF-I) binding proteins (IGFBPs) and IGF-I receptors, and to exhibit a mitogenic response to exogenous IGF-I. We have used T47D cells to investigate the regulation of IGFBPs by IGF-I and retinoic acid (RA), agents that affect cell proliferation and have been shown to regulate IGFBP levels in other cell types. Exposure of T47D cells to IGF-I resulted in the appearance of IGFBP-2, -4, and -5 in conditioned medium but had no effect on the levels of IGFBPs in Triton X-100-extracted cells. This effect was most pronounced for IGFBP-5 and was also elicited by an IGF-I analog that retains affinity for IGFBPs but not by insulin or IGF analogs that have decreased affinity for IGFBPs. Additionally, this effect was not associated with a change in IGFBP-5 messenger RNA (mRNA) levels; however, the appearance of IGFBP-5 in the conditioned medium was inhibited by an anti-IGF-I receptor antibody (alpha IR-3). RA decreased IGFBP-5 mRNA levels and cell-associated IGFBP-5 in both the presence and absence of IGF-I and inhibited the IGF-I-stimulated secretion of IGFBP-5 into T47D cell conditioned medium. These results suggest that IGF-I increases IGFBP-5 levels in the T47D cell line both through direct interaction with IGFBP-5 as well as through a receptor-mediated process that does not require direct interaction with IGFBPs. The latter results are consistent with an effect of IGF-I on a factor that may modulate an IGFBP protease activity. The inhibitory effect of RA, on the other hand, appears to be due primarily to regulation of IGFBP-5 mRNA levels. Thus, IGFBP-5 accumulation appears to be positively regulated by IGF-I, potentially at the level of susceptibility to proteolysis, and negatively regulated at the level of gene expression by RA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7521344     DOI: 10.1210/jcem.77.5.7521344

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Insulin-like growth factor binding proteins (IGFBPs) in breast cancer.

Authors:  C M Perks; J M Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

2.  Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3.

Authors:  V Hwa; Y Oh; R G Rosenfeld
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

Review 3.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis.

Authors:  James Beattie; Gordon J Allan; Jennifer D Lochrie; David J Flint
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

Review 4.  Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3?

Authors:  Hanna A Zielinska; Amit Bahl; Jeff Mp Holly; Claire M Perks
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-01-19

Review 5.  Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer.

Authors:  Mustafa Akkiprik; Yumei Feng; Huamin Wang; Kexin Chen; Limei Hu; Aysegul Sahin; Savitri Krishnamurthy; Ayse Ozer; Xishan Hao; Wei Zhang
Journal:  Breast Cancer Res       Date:  2008-08-11       Impact factor: 6.466

6.  MN1 overexpression with varying tumor grade is a promising predictor of survival of glioma patients.

Authors:  Masum Saini; Ajaya Nand Jha; Rajiv Tangri; Md Qudratullah; Sher Ali
Journal:  Hum Mol Genet       Date:  2021-01-06       Impact factor: 6.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.